Jyn Ling Kuan

Jyn Ling Kuan

Auto-generated profile, based on publicly available information

Jyn Ling Kuan

SingHealth Duke-NUS Institute of Precision Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
YBYasmin Bylstra
Yasmin Bylstra
JKJyn Ling Kuan
Jyn Ling Kuan
WLWeng Khong Lim
Weng Khong Lim
JBJaydutt Digambar Bhalshankar
Jaydutt Digambar Bhalshankar
JTJing Xian Teo
Jing Xian Teo
SJSaumya Shekhar Jamuar
Saumya Shekhar Jamuar

30 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
YBYasmin Bylstra
Yasmin Bylstra
WLWeng Khong Lim
Weng Khong Lim
SKSylvia Kam
Sylvia Kam
KTKoei Wan Tham
Koei Wan Tham
RWR. Ryanne Wu
R. Ryanne Wu
PTPatrick Tan
Patrick Tan
Background: Family history has traditionally been an essential part of clinical care to assess health risks. However, declining sequencing costs have precipitated a shift towards genomics-first approaches in population screening programs, with less emphasis on family history assessment. We evaluated the utility of family history for genomic sequencing selection. Methods: We analysed whole genome sequences of 1750 healthy research participants, with and without preselection based on standardised family history collection, screening 95 cancer genes. Results: The frequency of likely pathogenic/ pathogenic (LP/P) variants in 884 participants with no family history available (FH not available group) (2%) versus 866 participants with family history available (FH available group) (3.1%) was not significant ( p =0.158). However, within the FH available group, amongst 73 participants with an increased family history cancer risk (increased FH risk), 1 in 7 participants carried a LP/P variant inferring a six-fold increase compared with 1 in 47 participants assessed at average family history cancer risk (average FH risk) and a seven-fold increase compared to the FH not available group. The enrichment was further pronounced (up to 18-fold) when assessing the 25 cancer genes in the ACMG 59-gene panel. Furthermore, 63 participants had an increased family history cancer risk in absence of an apparent LP/P variant. Conclusion: Our findings show that systematic family history collection remains critical for health risk assessment, providing important actionable data and augmenting the yield from genomic data. Family history also highlights the potential impact of additional hereditary, environmental and behavioural influences not reflected by genomic sequencing.